Do we really need new trials on fulvestrant in prostate cancer?

Onkologie. 2010;33(1-2):12-3. doi: 10.1159/000271605. Epub 2010 Jan 22.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aged
  • Androgen Antagonists / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / blood
  • Castration
  • Combined Modality Therapy
  • Disease Progression
  • Drug Administration Schedule
  • Estradiol / adverse effects
  • Estradiol / analogs & derivatives*
  • Estradiol / therapeutic use
  • Fulvestrant
  • Humans
  • Injections, Intramuscular
  • Male
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Fulvestrant
  • Estradiol
  • Prostate-Specific Antigen